Several nicotinic and isoniazid derivatives, most of them containing nitro groups were synthesized by our group, and evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H 37 Rv using the Alamar Blue susceptibility test and the activity expressed as the minimum inhibitory concentration (MIC) in mg/mL. The compound 11d exhibited the best result (1.2 µg/mL) when compared with first line drugs such as isoniazid (INH) and rifampicin (RIP). Therefore this class of compounds could be a good starting point to develop new lead compounds in the treatment of multi-drug resistant tuberculosis.
Introduction
The pyridine nucleus is an important heteroaromatic class of compounds with a wide range of activities and it is present in many products such as drugs, vitamins, food, flavorings, plants, dyes, rubber products, adhesives, insecticides and herbicides 1 . In this context, nicotinic acid (pyridine-3-carboxylic acid), also known as niacin and vitamin B3, is found in various plants and animals and has vital roles in such biological processes as production of energy, signal transduction, regulation of gene expression and synthesis of fatty acids, cholesterol and steroids 2, 3 . Nicotinic acid derivatives and its isomers have also been investigated as an agent for the prevention or delay of the onset of type 1 diabetes mellitus 4 . They also have anti-bacterial, anti-oxidant, anti-inflammatory and anti-carcinogenic activities, and have putative activity against osteoarthritis and granuloma annulare 3 . For example, it can be mentioned the importance aim of this article is to evaluate the in vitro antibacterial activity against Mycobacterium tuberculosis of several compounds of this class synthesized by our group. Results and Discussion
Nitro nicotinic derivatives
The synthesis of nitro compounds described in the schemes (1-4) was based on the reaction between 2-chloro-3-pyridinecarbonylchloride and nitro anilines or nitro phenylhydrazines, leading to the compounds 2a-c, 7 4a-g, 8 6a-c, 9 8a-d, 10 and 9a-d 10 or the coupling of nitro acid chlorides or aldehydes with isoniazid, leading to the products 11a-d
11
. Nowadays, important attention has been payed for nitro compounds as anti-TB, especially due to the discovery of the compound nitroimidazole PA-824 (Figure 2) 5 , which has shown important TB activity against MDR-TB strains, promising activity in latent state TB and potent sterilization effects compared with those of rifampicin and isoniazid. Another advantage of PA-824 is that no significant inhibition of cytochrome P450 isozymes has been observed suggesting that it could be used with HIV medications, being useful in the TB/HIV treatment. Due to its promising activity against TB, the nitroimidazole PA-824 is under clinical phase studies being developed by TB Alliance. 
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N-Nitro-2-chloronicotinamides
The N-nitro-2-chloronicotinamides, as well others N-aryl-2-chloronicotinamides (Schemes 1 and 2) were synthesized and evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H 37 Rv using the Alamar Blue susceptibility test and the activity expressed as the minimum inhibitory concentration (MIC) in mg/mL. However, none of the compounds above mentioned were active. The compounds 2a-c and 4a-g were identified by spectral data, which are presented in the Tables 1-3 . *C-F couplings
1-(2-Chloronicotinoyl)-2-(nitrophenyl)hydrazines
The 1-(2-chloronicotinoyl)-2-(nitrophenyl)hydrazines 6a-c (Scheme 3) were synthesized and evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H 37 Rv using the Alamar Blue susceptibility test and the activity expressed as the minimum inhibitory concentration (MIC) in µg/mL. However, none of the compounds above mentioned were active. 
Nitroisoniazid derivatives
The
N'-[(E)-(nitrophenyl)methylidene]isonicotinohydrazides 11b-d (Scheme 5)
, were synthesized and identified by spectral data, which are presented in the Table 6 . These compounds were evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H 37 Rv using the Alamar Blue susceptibility test and the activity expressed as the minimum inhibitory concentration (MIC) in µg/mL ( Table 7) . Depending on the position of the nitro group in the aromatic ring, different MIC values were obtained when compared with phenyl group, demonstrating the importance of the nitro group for the biological activity in this class of compounds. In ortho or meta position, MIC values were higher (5.0 µg/mL) when compared with the phenyl system (3.2 µg/mL). However, when the nitro group was placed in the para position it increases by three folds the biological activity, with MIC values of 1.2 µg/mL. It can be observed some modifications in the anti-tubercular activity when N'-[(E)-(nitrophenyl)methylidene]isonicotinohydrazides 11b-d 12 
were compared with the N'-[(E)-
(disubstituted-phenyl)methylidene]isonicotino-hydrazides 12a-c 13 and N'-(disubstitutedbenzoyl)isoniazid 13a-c 14 derivatives containing nitro groups, which were previously evaluate by our group (Scheme 6). For example, the N'-(disubstitutedbenzoyl)isoniazid 13a-c were more activity when compared with isonicotinohydrazides 11b-d and 12a-c. The dinitro compound 12a and the nitrochloro compound 12b did not show increased anti-tubercular activity when compared with the mononitroisonicotinohydrazide 11d. However, the compound 12c, which has respectively, the nitro group and chloro atom at 2 and 3 positions in the aromatic ring presented increased anti-tubercular activity, when compared with the mononitroisonicotino-hydrazide 11b indicating that chloro atom at 3 position is important for the biological activity.
ARKAT USA, Inc. 16 . This methodology is nontoxic, uses a thermally-stable reagent and shows good correlation with proportional and BACTEC radiometric methods. 17, 18 Briefly, 200 µL of sterile deionized water was added to all outer-perimeter wells of sterile 96 well plates (falcon, 3072: Becton Dickinson, Lincoln Park NJ) to minimize evaporation of the medium in the test wells during incubation. The 96 plates received 100 µL of the Middlebrook 7H9 broth (Difco laboratories, Detroit, MI, USA) and a serial dilution of the compounds 2a-c; 4a-g; 6a-c; 8a-d;
